Executive summary

Published by the Loma Linda group, this study reported the results of their randomized trial compared PBT with TACE for HCC. Patients were randomized to receive PBT (n = 36) or TACE (n = 40). Proton therapy was administered in 15 fractions to a total dose of 70.2 GyE. The 2-year OS for PBT versus TACE was similar at 68% (p = .80), however, median PFS was improved for PBT versus TACE (p = .002). LC was improved with PBT versus TACE (p = .003). Days of posttreatment hospitalization were 24 for PBT and 166 for TACE (p < .001). Total mean cost per patient for treatment and posttreatment care revealed a 28% cost savings for PBT. The authors concluded that this data supports the use of PBT as a viable treatment alternative to TACE for patients with HCC within transplant criteria.

Discover more insights directly from the study author, Dr. David A. Bush, in our exclusive interview here!


Population and method



Key content topics
Top cancer treatments